Literature DB >> 22173266

Reversible and persistent decreases in cocaine self-administration after cholinesterase inhibition: different effects of donepezil and rivastigmine.

Kenneth Grasing1, Yungao Yang, Shuangteng He.   

Abstract

We recently observed that pretreatment with the cholinesterase inhibitor, tacrine can produce long-lasting reductions in cocaine-reinforced behavior, described as persistent attenuation. In addition to inhibiting both acetylcholinesterase (AChE) and butyrylcholinesterase, tacrine can potentiate actions of dopamine. This study was carried out to evaluate the effects of donepezil (which selectively inhibits AChE) and rivastigmine (which inhibits both AChE and butyrylcholinesterase) on cocaine self-administration. High self-administration rats self-administered different doses of cocaine under a fixed ratio-5 schedule. Over a 4-day period, vehicle, donepezil, or rivastigmine was infused as animals were maintained in home cages (21 h per day), with signs of cholinergic stimulation (fasciculation, vacuous jaw movements, yawning, and diarrhea) scored by a blinded observer. Both compounds dose-dependently decreased cocaine self-administration, but differed in the potency and temporal pattern of their effects. Self-administration of low-dose cocaine was decreased to a greater degree by rivastigmine than donepezil (50% effective doses of 2.33 and 6.21 mg/kg/day, respectively), but this early effect did not continue beyond sessions immediately after treatment with rivastigmine. Group means for cocaine self-administration were decreased at some time points occurring between 1 and 3 days after the treatment with 10 mg/kg/day of donepezil (late effects), with decreases of more than 80% observed in some individual rats that persisted for 1 week or longer. Early, but not late, effects were correlated with signs of cholinergic stimulation. In summary, pretreatment with donepezil, but not rivastigmine produced persistent reductions in cocaine-reinforced behavior, which were not associated with signs of cholinergic stimulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22173266     DOI: 10.1097/FBP.0b013e3283428cd8

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  8 in total

1.  Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil.

Authors:  Kenneth Grasing; Deepan Mathur; Cherilyn DeSouza; Thomas F Newton; David E Moody; Marc Sturgill
Journal:  Am J Addict       Date:  2016-07-08

2.  Enduring effects of tacrine on cocaine-reinforced behavior: Analysis by conditioned-place preference, temporal separation from drug reward, and reinstatement.

Authors:  Kenneth Grasing; Yungao Yang; Shuangteng He
Journal:  Pharmacol Res       Date:  2015-04-16       Impact factor: 7.658

3.  The muscarinic agonist pilocarpine modifies cocaine-reinforced and food-reinforced responding in rats: comparison with the cholinesterase inhibitor tacrine.

Authors:  Kenneth W Grasing; Haiyang Xu; Jessica Y Idowu
Journal:  Behav Pharmacol       Date:  2019-09       Impact factor: 2.293

4.  Effects of acute and repeated administration of the selective M4 PAM VU0152099 on cocaine versus food choice in male rats.

Authors:  Morgane Thomsen; Jill R Crittenden; Craig W Lindsley; Ann M Graybiel
Journal:  Addict Biol       Date:  2022-03       Impact factor: 4.093

5.  Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers.

Authors:  James J Mahoney; Ari D Kalechstein; Christopher D Verrico; Nicholas M Arnoudse; Benjamin A Shapiro; Richard De La Garza
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-11-12       Impact factor: 5.067

6.  Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder.

Authors:  Elise E DeVito; Kathleen M Carroll; Theresa Babuscio; Charla Nich; Mehmet Sofuoglu
Journal:  J Subst Abuse Treat       Date:  2019-08-16

Review 7.  A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders.

Authors:  Kenneth Grasing
Journal:  Behav Brain Res       Date:  2016-06-15       Impact factor: 3.332

8.  Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use.

Authors:  Kathleen M Carroll; Elise E DeVito; Sarah W Yip; Charla Nich; Mehmet Sofuoglu
Journal:  Am J Addict       Date:  2019-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.